// App-Quantinova.ai

5066 : Genomic aberrations associated with overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or placebo (PBO) plus androgen deprivation therapy (ADT) in TITAN.

Researchers

Presenter

  • Neeraj Agarwal

Principal Investigators

  • Justin Lucas

  • Clemente Aguilar-Bonavides

  • Shibu Thomas

  • Michael Gormley

  • Simon Chowdhury

  • Axel S. Merseburger

  • Anders Bjartell

  • Hirotsugu Uemura

  • Mustafa Özgüroğlu

  • Sharon McCarthy

  • Sabine D. Brookman-May

  • Florence Lefresne

  • Suneel Mundle

  • Kim N. Chi

Medical Centers

  • Hunstman Cancer Institute of Utah, Salt Lake City, UT

  • Janssen Research and Development, LLC, Spring House, PA

  • Guys, Kings and St. Thomas Hospitals, and Sarah Cannon Research Institute, London, United Kingdom

  • University of Schleswig-Holstein Campus Luebeck, Luebeck, Germany

  • Skane University Hospital Malmo, Lund University, Malmo, Sweden

  • Niigata University School of Medicine, Niigata, Japan

  • Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey

  • Janssen Research & Development, LLC, Raritan, NJ

  • Janssen Research & Development, Los Angeles, CA, and Ludwig Maximilian University, Munich, Germany

  • Janssen Research & Development, Los Angeles, CA

  • BC Cancer

  • Vancouver Prostate Centre, Vancouver, BC, Canada

Locations

  • United States

  • United Kingdom

  • Germany

  • Sweden

  • Japan

  • Turkey

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • NCT02489318

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved